Arkolith/Insider Trading/LENZ/Form 4

Chevallard Daniel R.

Chief Financial OfficerLENZ Therapeutics, Inc. (LENZ) · full profile →Form 4 · filed Mar 30, 2026
Net Buying
Open-Market Buys
$64K
Open-Market Sells
$0
Net Open-Market Flow
$64K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 27, 2026Buy(P)8K$8.57$64K13K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001706176-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML